Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 6,40€(−0,62%). Der Median liegt bei 5,67€(−11,96%).
Kaufen | 5 |
Halten | 1 |
Verkaufen | 2 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 6 / 18 |
Levermann-Strategie | -1 / 13 |
News
Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA
- Pivot to U.S.-based Supply Chain for Critical Input Materials Completed - STONY BROOK, NY / ACCESS Newswire / April 21, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that LineaRx, Inc., the Company's majority-owned subsidiary, has completed a long-term initiative to source critical input materials for its LineaDNA™ and LineaIVT™ platforms from U.S.-based suppliers. The initiative, undertaken in response to the 2024 BIOSECURE Act and customer demand for a U.S.-based supply chain, comes as the biopharmaceutical industry increasingly considers reshoring manufacturing operations to the U.S. in response to potential tariff impacts and to ensure a stable supply chain.» Mehr auf accessnewswire.com
Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
STATEN ISLAND, N.Y. , April 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Indian Patent Office in March 2025.» Mehr auf prnewswire.com
Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain
Ginkgo Bioworks and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON , April 10, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new contract with the Advanced Research Projects Agency for Health (ARPA-H), alongside partners Tritica Biosciences , US Pharmacopeia (USP), On Demand Pharmaceuticals , and Isolere Bio by Donaldson . This two-year program, Wheat-based High efficiency Enzyme and API Technology (WHEAT), aims to establish a new manufacturing process for the distributed production of biologic and small molecule active pharmaceutical ingredients (APIs) using wheat germ cell-free expression systems.» Mehr auf prnewswire.com
Unternehmenszahlen
(EUR) | Dez. 2024 | |
---|---|---|
Umsatz | 42,14 Mio | 34,03% |
Bruttoeinkommen | 32,89 Mio | 93,33% |
Nettoeinkommen | −103,34 Mio | 46,04% |
EBITDA | −137,89 Mio | 43,36% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 371,52 Mio€ |
Anzahl Aktien | 58,03 Mio |
52 Wochen-Hoch/Tief | 39,42€ - 4,36€ |
Dividenden | Nein |
Beta | 1,35 |
KGV (PE Ratio) | −0,70 |
KGWV (PEG Ratio) | −0,04 |
KBV (PB Ratio) | 0,53 |
KUV (PS Ratio) | 1,88 |
Unternehmensprofil
Ginkgo Bioworks Holdings, Inc. entwickelt zusammen mit seinen Tochtergesellschaften eine Plattform für die Zellprogrammierung. Die Plattform wird zur Programmierung von Zellen verwendet, um die biologische Herstellung von Produkten wie neuartigen Therapeutika, Lebensmittelzutaten und aus Erdöl gewonnenen Chemikalien zu ermöglichen. Das Unternehmen bedient verschiedene Endmärkte, darunter Spezialchemikalien, Landwirtschaft, Lebensmittel, Konsumgüter und Pharmazeutika. Ginkgo Bioworks hat eine Partnerschaft mit Selecta Biosciences, Inc. zur Entwicklung der ImmTOR-Technologieplattform. Ginkgo Bioworks Holdings, Inc. wurde im Jahr 2008 gegründet und hat seinen Hauptsitz in Boston, Massachusetts.
Name | Ginkgo Bioworks |
CEO | Dr. Jason Kelly Ph.D. |
Sitz | Boston, ma USA |
Website | |
Industrie | Biotechnologie |
Börsengang | |
Mitarbeiter | 834 |
Ticker Symbole
Börse | Symbol |
---|---|
NYSE | DNA |
Assets entdecken
Shareholder von Ginkgo Bioworks investieren auch in folgende Assets